ArticleOncogene2002
RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- "Transfer" of power: The intersection of DNA virus infection and tRNA biology.Seminars in cell & developmental biology · 2023Review
- Selection of tRNA Genes in Human Breast Tumours Varies Substantially between Individuals.Cancers · 2023Article
- Translation Control byCancers · 2018Article
- Article
- Review
- Codon-biased translation can be regulated by wobble-base tRNA modification systems during cellular stress responses.RNA biology · 2015Review
- Dysregulation of the basal RNA polymerase transcription apparatus in cancer.Nature reviews. Cancer · 2013Review
- RNA polymerase III transcription in cancer: the BRF2 connection.Molecular cancer · 2011Review
- The antagonism between MCT-1 and p53 affects the tumorigenic outcomes.Molecular cancer · 2010Article
- Down-regulation of the transcriptional mediator subunit Med1 contributes to the loss of expression of metastasis-associated dapk1 in human cancers and cancer cells.International journal of cancer · 2009Article
- Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells.Cancer biology & therapy · 2008Article
- Differential expression of the TFIIIB subunits Brf1 and Brf2 in cancer cells.BMC molecular biology · 2008Article
- Transcriptional regulation of human small nuclear RNA genes.Biochimica et biophysica acta · 2008Review
- Mutation of RNA Pol III subunit rpc2/polr3b Leads to Deficiency of Subunit Rpc11 and disrupts zebrafish digestive development.PLoS biology · 2007Article
- The green tea component EGCG inhibits RNA polymerase III transcription.Biochemical and biophysical research communications · 2007Article
- The p53 tumor suppressor protein represses human snRNA gene transcription by RNA polymerases II and III independently of sequence-specific DNA binding.Molecular and cellular biology · 2005Article
- Deregulation of RNA polymerase III transcription in cervical epithelium in response to high-risk human papillomavirus.Oncogene · 2005Article
- RNA polymerase III transcription and cancer.Oncogene · 2004Review
- p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB.The EMBO journal · 2003Article
- Several regions of p53 are involved in repression of RNA polymerase III transcription.Oncogene · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA polymerase (pol) III synthesizes essential small RNAs, including tRNA and 5S rRNA. Wild-type p53 can repress pol III transcription both in vitro and in vivo. Many tumours carry substitutions in p53 which have selective effects on its functions. We identify tumour-derived mutations that compromise the ability of p53 to regulate pol III transcription. Furthermore, substitution R175H, the most common mutation in cancers, converts p53 from a repressor to an activator of pol III. Oncoproteins neutralize p53 in some tumours; we show that human papillomavirus E6 and cellular hdm2 can both release pol III from repression by p53. These data suggest that the restraining influence of p53 on pol III will be lost in many tumours. In addition to these features of sporadic cancers, some individuals inherit mutant forms of p53 and consequently suffer from Li-Fraumeni syndrome, showing genetic predisposition to certain malignancies. We find that pol III transcriptional activity is often highly elevated in primary fibroblasts from Li-Fraumeni patients, especially if the germline p53 mutation is followed by loss of the remaining allele. Our data suggest that p53 status can have a profound effect upon pol III transcription and hence on the biosynthetic capacity of cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.